PE20171307A1 - Compuestos de triazolopirimidina y usos de los mismos - Google Patents

Compuestos de triazolopirimidina y usos de los mismos

Info

Publication number
PE20171307A1
PE20171307A1 PE2017001154A PE2017001154A PE20171307A1 PE 20171307 A1 PE20171307 A1 PE 20171307A1 PE 2017001154 A PE2017001154 A PE 2017001154A PE 2017001154 A PE2017001154 A PE 2017001154A PE 20171307 A1 PE20171307 A1 PE 20171307A1
Authority
PE
Peru
Prior art keywords
halogen
compounds
dihydrobenzofuran
triazolo
pyrimidin
Prior art date
Application number
PE2017001154A
Other languages
English (en)
Inventor
Ho Man Chan
Xiang-Ju Justin Gu
Ying Huang
Ling Li
Yuan Mi
Wei Qi
Martin Sendzik
Yongfeng Sun
Long Wang
Zhengtian Yu
Hailong Zhang
Ji Yue Zhang (Jeff)
Man Zhang
Qiong Zhang
Kehao Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20171307A1 publication Critical patent/PE20171307A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TRIAZOLOPIRIMIDINA DE FORMULA (I) DONDE ----- ES UN ENLACE SIMPLE O UN ENLACE DOBLE; R1 Y R2 SON H O HALOGENO; R3 ES HALOGENO, FENILO, ENTRE OTROS; R4 ES H, HALOGENO O ALQUILO C1-C4; R5 ES OH O ALQUILO C1-C4; n ES 0 O 1. SON COMPUESTOS PREFERIDOS: 8-(1,3-DIMETIL-1H-PIRAZOL-5-IL)-N-((5-FLUORO-2,3-DIHIDROBENZOFURAN-4-IL)METIL)-[1,2,4]TRIAZOLO[4,3-c]PIRIMIDIN-5-AMINA; N-((5-FLUORO-2,3-DIHIDROBENZOFURAN-4-IL)METIL)-8-(2-METILPIRIDIN-3-IL)-[1,2,4]TRIAZOLO[4,3-c]PIRIMIDIN-5-AMINA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL COMPLEJO REPRESIVO DEL POLINOMIO 2 (PRC2) SIENDO UTILES EN EL TRATAMIENTO DE LINFOMAS, TUMORES Y CANCER
PE2017001154A 2014-12-23 2015-12-21 Compuestos de triazolopirimidina y usos de los mismos PE20171307A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014094644 2014-12-23
CN2015095320 2015-11-23

Publications (1)

Publication Number Publication Date
PE20171307A1 true PE20171307A1 (es) 2017-09-05

Family

ID=55071101

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001154A PE20171307A1 (es) 2014-12-23 2015-12-21 Compuestos de triazolopirimidina y usos de los mismos

Country Status (40)

Country Link
US (5) US9580437B2 (es)
EP (1) EP3237418B1 (es)
JP (1) JP6736559B2 (es)
KR (1) KR102534028B1 (es)
CN (1) CN107108637B (es)
AU (1) AU2015370524B2 (es)
BR (1) BR112017010354B8 (es)
CA (1) CA2969090C (es)
CL (1) CL2017001572A1 (es)
CO (1) CO2017005992A2 (es)
CR (1) CR20170285A (es)
CY (1) CY1121901T1 (es)
DK (1) DK3237418T3 (es)
DO (1) DOP2017000149A (es)
EA (1) EA032416B1 (es)
EC (1) ECSP17047153A (es)
ES (1) ES2722048T3 (es)
GT (1) GT201700146A (es)
HR (1) HRP20190805T1 (es)
HU (1) HUE043060T2 (es)
IL (1) IL252135B (es)
JO (1) JO3489B1 (es)
LT (1) LT3237418T (es)
ME (1) ME03385B (es)
MX (1) MX2017008529A (es)
MY (1) MY186837A (es)
NZ (1) NZ731664A (es)
PE (1) PE20171307A1 (es)
PH (1) PH12017501016A1 (es)
PL (1) PL3237418T3 (es)
PT (1) PT3237418T (es)
RS (1) RS58679B1 (es)
SG (1) SG11201703880VA (es)
SI (1) SI3237418T1 (es)
SV (1) SV2017005472A (es)
TN (1) TN2017000204A1 (es)
TW (1) TWI694076B (es)
UA (1) UA120945C2 (es)
UY (1) UY36462A (es)
WO (1) WO2016103155A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170285A (es) * 2014-12-23 2017-08-21 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
WO2017210395A1 (en) * 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3472161B1 (en) 2016-06-20 2020-03-25 Novartis AG Triazolopyridine compounds and uses thereof
JP2019524872A (ja) * 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
BR112018076443A2 (pt) * 2016-06-20 2019-04-09 Novartis Ag formas cristalinas de um composto de triazolopirimidina
AU2017296289A1 (en) 2016-07-12 2019-01-31 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
MX2019008696A (es) 2017-01-23 2019-09-13 Revolution Medicines Inc Compuestos de piridina como inhibidores de shp2 alostericos.
AU2018210770B2 (en) 2017-01-23 2022-03-24 Revolution Medicines, Inc. Bicyclic compounds as allosteric SHP2 inhibitors
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
US11312705B2 (en) * 2017-03-16 2022-04-26 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN109575013A (zh) * 2017-09-28 2019-04-05 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
AU2018347516A1 (en) 2017-10-12 2020-05-07 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
CN111433205B (zh) * 2017-12-15 2024-01-19 锐新医药公司 作为变构shp2抑制剂的多环化合物
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
CN111630042A (zh) 2018-01-23 2020-09-04 巴斯夫欧洲公司 吡啶衍生物的卤化
AU2019214861B2 (en) 2018-01-31 2021-11-18 Mirati Therapeutics, Inc. PRC2 inhibitors
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN110734436A (zh) * 2018-07-19 2020-01-31 上海青煜医药科技有限公司 嘧啶或吡嗪并环化合物及其应用
BR112021009880A2 (pt) * 2018-11-30 2021-08-17 Tuojie Biotech (Shanghai) Co., Ltd. pirimidina e derivado de heterociclo de nitrogênio de cinco membros, método de preparação para os mesmos e usos médicos dos mesmos
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
JP2022525199A (ja) * 2019-03-15 2022-05-11 フルクラム セラピューティクス，インコーポレイテッド Ｅｅｄおよびｐｒｃ２調節物質としての大環状アゾロピリジン誘導体
JP7299307B2 (ja) * 2019-04-03 2023-06-27 テラ・ストーン株式会社 チミン核酸塩基をベースとするトリアゾロピリミジン類及びその製造方法
JP2022530866A (ja) * 2019-04-22 2022-07-04 ミラティ セラピューティクス，インク． Ｐｒｃ２阻害剤としてのナフチリジン誘導体
CN113874377A (zh) 2019-05-13 2021-12-31 埃科莱布美国股份有限公司 作为铜腐蚀抑制剂的1,2,4-三唑并[1,5-a]嘧啶衍生物
KR20220027933A (ko) * 2019-06-05 2022-03-08 미라티 테라퓨틱스, 인크. 암을 치료하기 위한 prc2 억제제로서의 이미다조[1,2-c]피리미딘 유도체
CA3142477A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
WO2021032004A1 (zh) 2019-08-22 2021-02-25 上海青煜医药科技有限公司 氮杂芳基化合物及其应用
CN114746414A (zh) * 2019-09-26 2022-07-12 诺华公司 氮杂-喹啉化合物及其用途
EP4056570A4 (en) * 2019-11-01 2023-12-20 ShanghaiTech University EED INHIBITOR AND PRODUCTION METHOD AND USE THEREOF
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
EP4149932A1 (en) * 2020-05-11 2023-03-22 Ascentage Pharma (Suzhou) Co., Ltd. Preparation method of (5-fluoro-2, 3-dihydrobenzofuran-4-yl) methanamine or its salt, and intermediates thereof
AU2021281123A1 (en) 2020-05-28 2023-02-09 Novartis Ag Dosing regimens for N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-C]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating PRC2-mediated diseases or disorders
CN114907385A (zh) 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
WO2023016511A1 (zh) * 2021-08-11 2023-02-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
SE519662C2 (sv) * 2001-07-04 2003-03-25 Asept Int Ab Ventilanordning vid utportioneringsanordningar
AU2002357667A1 (en) * 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
MXPA04008722A (es) 2002-03-08 2005-07-13 Eisai Co Ltd Compuestos macrociclicos utiles como farmaceuticos.
PT3000810T (pt) 2002-03-13 2017-10-25 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
ATE449168T1 (de) 2004-06-01 2009-12-15 Univ North Carolina Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
ES2481402T3 (es) 2005-07-21 2014-07-30 Ardea Biosciences, Inc. Inhibidores de N-(arilamino)sulfonamida de MEK
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CA2648021A1 (en) 2006-03-31 2007-10-11 Ordway Research Institute, Inc. Prognostic and diagnostic method for cancer therapy
WO2008083251A2 (en) 2006-12-27 2008-07-10 Usc Stevens - University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
US8907091B2 (en) 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
RU2523890C2 (ru) 2007-09-12 2014-07-27 Дженентек, Инк. Комбинации ингибиторов фосфоинозитид 3-киназы и химиотерапевтических агентов и способы применения
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
US8895526B2 (en) 2009-03-27 2014-11-25 Cold Spring Harbor Laboratory Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
NZ603454A (en) * 2010-05-07 2014-06-27 Glaxosmithkline Llc Indoles useful for treating cellular proliferation diseases such as cancer
ES2570380T3 (es) 2010-09-10 2016-05-18 Epizyme Inc Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
WO2013010181A2 (en) 2011-07-14 2013-01-17 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
AU2012315566A1 (en) 2011-09-30 2014-04-17 Glaxosmithkline Llc Methods of treating cancer
WO2014124418A1 (en) 2013-02-11 2014-08-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AU2013232229B2 (en) 2012-03-12 2017-11-23 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2014078813A1 (en) 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US20150313906A1 (en) 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
EP2954056A4 (en) 2013-02-08 2016-09-21 Stemcentrx Inc NEW MULTISPECIFIC CONSTRUCTIONS
EP2968565A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9776996B2 (en) * 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
AU2015217152A1 (en) 2014-02-11 2016-08-11 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
UA123897C2 (uk) 2014-11-14 2021-06-23 Басф Се Бензилпропаргілові прості ефіри як інгібітори нітрифікації
ES2668688T3 (es) 2014-12-16 2018-05-21 Omya International Ag Carbonato de calcio para protección vegetal
CR20170285A (es) * 2014-12-23 2017-08-21 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers

Also Published As

Publication number Publication date
US10220036B2 (en) 2019-03-05
CA2969090A1 (en) 2016-06-30
US20200323859A1 (en) 2020-10-15
PH12017501016B1 (en) 2017-12-11
CY1121901T1 (el) 2020-10-14
PT3237418T (pt) 2019-05-23
PL3237418T3 (pl) 2019-07-31
PH12017501016A1 (en) 2017-12-11
SI3237418T1 (sl) 2019-06-28
AU2015370524B2 (en) 2018-11-01
EP3237418A1 (en) 2017-11-01
CN107108637B (zh) 2019-10-29
BR112017010354B8 (pt) 2022-10-18
US11931363B2 (en) 2024-03-19
IL252135B (en) 2020-06-30
ECSP17047153A (es) 2019-02-28
JP6736559B2 (ja) 2020-08-05
MY186837A (en) 2021-08-25
LT3237418T (lt) 2019-05-10
SG11201703880VA (en) 2017-07-28
WO2016103155A1 (en) 2016-06-30
KR20170095882A (ko) 2017-08-23
US20160176882A1 (en) 2016-06-23
JO3489B1 (ar) 2020-07-05
HRP20190805T1 (hr) 2019-06-28
CN107108637A (zh) 2017-08-29
NZ731664A (en) 2024-02-23
SV2017005472A (es) 2018-06-12
KR102534028B1 (ko) 2023-05-19
CL2017001572A1 (es) 2018-01-12
US9580437B2 (en) 2017-02-28
CA2969090C (en) 2023-05-02
GT201700146A (es) 2019-06-12
UA120945C2 (uk) 2020-03-10
ME03385B (me) 2020-01-20
MX2017008529A (es) 2017-10-25
US20230033320A1 (en) 2023-02-02
HUE043060T2 (hu) 2019-07-29
AU2015370524A1 (en) 2017-06-01
TN2017000204A1 (en) 2018-10-19
BR112017010354B1 (pt) 2022-09-20
CO2017005992A2 (es) 2017-10-20
DOP2017000149A (es) 2017-07-15
US11207325B2 (en) 2021-12-28
UY36462A (es) 2016-07-29
IL252135A0 (en) 2017-07-31
ES2722048T3 (es) 2019-08-07
JP2018500342A (ja) 2018-01-11
EP3237418B1 (en) 2019-01-30
BR112017010354A2 (pt) 2017-12-26
US20170348312A1 (en) 2017-12-07
TW201629065A (zh) 2016-08-16
TWI694076B (zh) 2020-05-21
US20190142837A1 (en) 2019-05-16
DK3237418T3 (da) 2019-05-13
EA032416B1 (ru) 2019-05-31
CR20170285A (es) 2017-08-21
EA201791420A1 (ru) 2017-10-31
RS58679B1 (sr) 2019-06-28

Similar Documents

Publication Publication Date Title
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
EA201591255A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
EA201791094A1 (ru) Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки
EA202090291A2 (ru) Производные бипиразола в качестве ингибиторов jak
EA201691484A1 (ru) Соли и твердая форма ингибитора btk
MX363715B (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201790085A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201591781A1 (ru) Химические соединения
PE20160689A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
EA201790603A1 (ru) Ингибиторы гистондеметилазы
TW201613864A (en) Novel compounds
MX2018004664A (es) Antagonistas de ep4.